Domača stran49BA • FRA
add
BeOne Medicines AG
Prejšnji trg. dan.
302,00 €
Dnevni razpon
302,00 € - 308,00 €
Letni razpon
166,00 € - 322,00 €
Tržna kapitalizacija
344,95 mrd. HKD
Povprečni obseg
5,00
Razm. P/E
-
Dividendna donosnost
-
V novicah
Investing.com
pred 13 urami
BeOne Medicines stock price target raised to $408 from $395 at RBC Capital
2,03 %
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 1,41 mrd. | 41,00 % |
Stroški poslovanja | 1,05 mrd. | 10,64 % |
Čisti dohodek | 124,84 mio. | 202,88 % |
Čista dobičkovnost prihodkov | 8,84 | 172,94 % |
Earnings per share | 1,09 | 267,89 % |
EBITDA | 198,86 mio. | 496,46 % |
Efektivna davčna stopnja | 15,17 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 4,04 mrd. | 48,74 % |
Skupna sredstva | 7,63 mrd. | 31,04 % |
Skupne obveznosti | 3,50 mrd. | 47,29 % |
Celoten lastniški kapital | 4,13 mrd. | — |
Shares outstanding | 110,66 mio. | — |
Razmerje P/B | 8,09 | — |
Donosnost sredstev | 5,85 % | — |
Donosnost kapitala | 8,20 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 124,84 mio. | 202,88 % |
Denar iz dejavnosti | 402,55 mio. | 113,70 % |
Denar iz naložb | −49,27 mio. | 63,20 % |
Denar iz financiranja | 961,27 mio. | 7.491,79 % |
Neto sprememba denarnih sredstev | 1,32 mrd. | 1.286,91 % |
Prost denarni tok | 306,27 mio. | 120,68 % |
Vizitka
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Generalni direktor
Datum ustanovitve
28. okt. 2010
Spletno mesto
Zaposleni
11.000
